An update is available for this article. Background: The clinical significance of the antibody
response after SARS-CoV-2 infection remains unclear. Purpose: To synthesize evidence on …

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects
humoral immune response after vaccination. It remains unclear whether RTX-treated …

At the end of 2019 a newly emerged betacoronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of severe …

Monoclonal antibodies (mAbs) that efficiently neutralize SARS-CoV-2 have been developed
at an unprecedented speed. Notwithstanding, there is a vague understanding of the various …

Introduction There is an increasing body of evidence surrounding the importance of a T cell-
mediated response to SARS-CoV-2 infection and after COVID-19 vaccination. In this internal …

Here, we expressed two neutralizing monoclonal antibodies (Abs) against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2; H4 and B38) in three formats: IgG1, IgA1 …

Background The determinants of successful humoral immune response to the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are of critical importance for the design …

Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response …

Background and Methods The SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) Omicron (B. 1.1. 529) variant is the antigenically most distinct variant to date …

Objectives To identify the best experimental approach to detect a SARS-CoV-2-specific T
cell response using a whole-blood platform. Methods Whole-blood from 56 COVID-19 and …